Defining the objectives of the AIDS vaccine for Asia network: Report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 435-452

  Rerks Ngarm, Supachai ^a   Pitisuttithum, Punnee ^b   Ganguly, Nirmal ^c   Zhang, Linqi ^d   Tamashiro, Hiko ^e   Cooper, David A ^f   Vun, Mean Chhi ^g   Bela, Budiman ^h   Ditangco, Rossana ⁱ   Van Kinh, Nguyen ^j   Bernstein, Alan ^k   Osmanov, Saladin ^l   Mathieson, Bonnie ^m   Kent, Stephen J ⁿ   Shao, Yiming ^o  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d TSINGHUA UNIVERSITY   (China)

^e HOKKAIDO UNIVERSITY   (Japan)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g National Center for HIV/AIDS   (Cambodia)

^h UNIVERSITY OF INDONESIA   (Indonesia)

ⁱ RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^j National Institute for Infectious and Tropical Diseases   (Viet Nam)

^k Global HIV Vaccine Enterprise   (United States)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m NATIONAL INSTITUTES OF HEALTH   (United States)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o National Center for AIDS   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASIA; CELLULAR IMMUNITY; CLINICAL TRIAL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; PRIORITY JOURNAL; REVIEW; VULNERABLE POPULATION; WORLD HEALTH ORGANIZATION;

AIDS VACCINES; ASIA; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION;

EID: 77955513309     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833c95c1     Document Type: Review

References (31)

1. Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature 2008; 455:609-611.
2. Deshpande A, Jauvin V, Pinson P, et al. Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008. AIDS Res Hum Retroviruses 2009; 25:633635.
3. Wirachsilp P, Kantakamalakul W, Foongladda S, et al. Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 2007; 38:814-827.
4. Lenihan F. China and Thailand to start trials of AIDS vaccines. BMJ 1993; 306:1564-1565.
5. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind,. placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
6. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48-55.
7. Earl PL, Cotter C, Moss B, et al. Design and evaluation of multigene, multi-clade HIV-1 MVA vaccines. Vaccine 2009; 27:5885-5895.
8. De Rose R, Chea S, Dale CJ, et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005; 23:1949-1956.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med; 361:2209-2220.
10. Shao Y, Li T, Shen X, et al. The safety and immunogenicity of the replicative Tiantan vaccinia HIV vaccine in phase I clinical trial. Poster No. P13-18, AIDS Vaccine 2008; Cape Town, South Africa; 13-16 October 2008.
11. Shao Y, Li T, Wolf H, et al. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial. Poster No.P14-1 5LB, AIDS Vaccine 2009; Paris; 19-22 October 2009.
12. Mehendale S, van Lunzen J, Clumeck N, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008; 24:873880.
13. Berkley S. HIV vaccine trials in India. Nat Biotechnol 2008; 26:495; author reply 496.
14. Kumar S, Aggarwal P, Vajpayee M, et al. Development of a candidate DNA/ MVA HIV-1 subtype C vaccine for India. Vaccine 2006; 24:2585-2593.
15. Kelleher AD, Puls RL, Bebbington M, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294-297.
16. Li D, Liu Y, Zhang Y, et al. Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination. Vaccine 2007; 25:6992-7000.
17. Huang X, Lu B, Yu W, et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 2009; 4:e4180.
18. Dai K, Liu Y, Liu M, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008; 26:5062-5071.
19. Liu J, Yu Q, Stone GW, et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008; 26:4062-4072.
20. Center RJ, Wheatley AK, Campbell SM, et al. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009; 27:6605-6612.
21. De Rose R, Fernandez CS, Smith MZ, et al. Control of viremia following immunotherapy of SIV-infected macaques with peptide pulsed blood. Plos Pathogens 2008; 4:e1000055.
22. Sexton A, Whitney P, Chong S, et al. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano; 3:3391-3400.
23. Hiroi T, Goto H, Someya K, et al. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1-and Th2-deficient conditions. J Immunol 2001; 167:5862-5867.
24. Sexton A, De Rose R, Reece JC, et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009; 83:7619-7628.
25. Kawada M, Tsukamoto T, Yamamoto H, et al. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol 2008; 82:10199-10206.
26. Yu S, Feng X, Shu T, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008; 26:6124-6131.
27. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines 2008; 7:311-317.
28. Ramanathan VD, Kumar M, Mahalingam J, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV-1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Human Retroviruses 2009; 25:1107-1116.
29. De Rose R, Zelikin A, Johnston APR, et al. Binding, internalisation and antigen presentation ofvaccine-loaded nanoengineered capsules in blood. Adv Mater 2008; 20:4698-4703.
30. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82:5450-5459.
31. Zaunders JJ, Munier ML, Seddiki N, et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (0X40). J Immunol 2009; 183:28272836.